Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
DF-6002 by Dragonfly Therapeutics for Cutaneous Squamous Cell Carcinoma (cSCC): Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Cutaneous Squamous Cell Carcinoma (cSCC). According...
DF-6002 by Dragonfly Therapeutics for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to...
DF-6002 by Dragonfly Therapeutics for Merkel Cell Carcinoma: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...
DF-6002 by Dragonfly Therapeutics for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Head And Neck Squamous Cell Carcinoma...
DF-6002 by Dragonfly Therapeutics for Transitional Cell Carcinoma (Urothelial Cell Carcinoma): Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Transitional Cell Carcinoma (Urothelial Cell Carcinoma)....
DF-6002 by Dragonfly Therapeutics for Cutaneous T-Cell Lymphoma: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Cutaneous T-Cell Lymphoma. According to GlobalData,...
DF-6002 by Dragonfly Therapeutics for Esophageal Cancer: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
DF-6002 by Dragonfly Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...
DF-6002 by Dragonfly Therapeutics for Renal Cell Carcinoma: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Renal Cell Carcinoma. According to GlobalData,...
DF-6002 by Dragonfly Therapeutics for Endometrial Cancer: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...
DF-6002 by Dragonfly Therapeutics for Solid Tumor: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
DF-6002 by Dragonfly Therapeutics for Small-Cell Lung Cancer: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
DF-6002 by Dragonfly Therapeutics for Hepatocellular Carcinoma: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase...
DF-6002 by Dragonfly Therapeutics for Gastric Cancer: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
DF-6002 by Dragonfly Therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). According...
DF-6002 by Dragonfly Therapeutics for Melanoma: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Melanoma. According to GlobalData, Phase II...
DF-6002 by Dragonfly Therapeutics for Cervical Cancer: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Cervical Cancer. According to GlobalData, Phase...
DF-6002 by Dragonfly Therapeutics for Ovarian Cancer: Likelihood of Approval
DF-6002 is under clinical development by Dragonfly Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase...